Spruce Biosciences Inc. (SPRB): Price and Financial Metrics
GET POWR RATINGS... FREE!
SPRB Stock Price Chart Interactive Chart >
SPRB Price/Volume Stats
| Current price | $1.42 | 52-week high | $15.08 |
| Prev. close | $1.36 | 52-week low | $1.25 |
| Day low | $1.31 | Volume | 38,500 |
| Day high | $1.44 | Avg. volume | 305,215 |
| 50-day MA | $1.80 | Dividend yield | N/A |
| 200-day MA | $3.63 | Market Cap | 33.36M |
Spruce Biosciences Inc. (SPRB) Company Bio
Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.
Latest SPRB News From Around the Web
Below are the latest news stories about Spruce Biosciences Inc that investors may wish to consider to help them evaluate SPRB as an investment opportunity.
Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceSAN FRANCISCO, February 03, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., MPH, Chief Executive Officer, and Samir Gharib, President and Chief Financial Officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022 at 5 |
Spruce Biosciences falls 9% amid pipeline update, outlookSpruce Biosciences (SPRB) provided an update on its clinical programs and financials.The company said it accelerating patient recruitment in the CAHmelia studies, which |
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022SAN FRANCISCO, January 24, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, upcoming milestones and strategic priorities for enhancing the design of and accelerating patient recruitment into the CAHmelia studies, which are evaluating tildacerfont for the treatment of adult classic congen |
Marquette Asset Management, LLC Buys Vanguard Total Bond Market ETF, ARK Next Generation ...Investment company Marquette Asset Management, LLC (Current Portfolio) buys Vanguard Total Bond Market ETF, ARK Next Generation Internet ETF, TAT Technologies, Avantis International Equity ETF, Dril-Quip Inc, sells Vanguard Short-Term Corporate Bond ETF, Vanguard Total Stock Market ETF, Vanguard FTSE Developed Markets ETF, Concord Acquisition Corp, Astrotech Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Marquette Asset Management, LLC. |
Spruce Biosciences (SPRB) Gets a Buy Rating from H.C. WainwrightIn a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Spruce Biosciences (SPRB – Research Report), with a price target of $20.00. The company's shares closed last Wednesday at $3.56, close to its 52-week low of $2.25. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -22.1% and a 20.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spruce Biosciences with a $9.50 average price target. |
SPRB Price Returns
| 1-mo | -19.32% |
| 3-mo | -37.44% |
| 6-mo | -44.96% |
| 1-year | -89.95% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -68.16% |
| 2021 | -81.65% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...